JNJJOHNSON & JOHNSON
- BusinessWire
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Johnson & Johnson ("Johnson & ...
- Analyst Upgrades
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287
Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson with a Overweight and raises the price target from $275 to $287. ...
- Analyst Upgrades
Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292
Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson with a Overweight and lowers the price target from $294 to $292. ...
- Analyst Upgrades
Leerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $272
Leerink Partners analyst David Risinger maintains Johnson & Johnson with a Outperform and lowers the price target from $276 to $272. ...
- Analyst Upgrades
These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results
Johnson & Johnson beat Q3 estimates and raised full-year guidance; sales rose 5.9%, EPS fell 7.5%. Analysts trimmed price targets. ...
- Analyst Upgrades
Wells Fargo Maintains Overweight on Johnson & Johnson, Lowers Price Target to $275
Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson with a Overweight and lowers the price target from $282 to $275. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $280
RBC Capital analyst Trung Huynh maintains Johnson & Johnson with a Outperform and lowers the price target from $290 to $280. ...
- BusinessWire
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on ...
- BusinessWire
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%* 2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time ...
- CNBC
Cramer’s week ahead: Earnings kick off as banks and chipmakers face big tests
CNBC’s Jim Cramer said next week’s earnings reports will give investors a clearer picture of corporate performance and the strength of the AI trade. ...
- PR Newswire
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable ...
- GlobeNewswire
2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of ...
- Analyst Upgrades
Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $287 Price Target
Guggenheim analyst Vamil Divan reiterates Johnson & Johnson with a Buy and maintains $287 price target. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $290
RBC Capital analyst Trung Huynh maintains Johnson & Johnson with a Outperform and raises the price target from $287 to $290. ...
- PR Newswire
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE®... ...
- BusinessWire
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
Johnson & Johnson, Naomi Watts and the American Optometric Association encourage women to make eye health part of midlife care Johnson & Johnson (NYSE:JNJ) today released new findings that show most women ...
- PR Newswire
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
Johnson & Johnson (NYSE: JNJ) today announced new findings on IMAAVY® (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG)... ...
- PR Newswire
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Johnson & Johnson (NYSE: JNJ) today announced that TREMFYA® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement ... ...
- PR Newswire
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, announced today new long-term follow-up data from the initial... ...
- PR Newswire
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing... ...
- BusinessWire
DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026
New innovations across fracture fixation, connected care, AI-assisted surgery and procedural solutions reinforce the company's leadership in trauma care. DePuy Synthes, a global leader in orthopaedic technologies ...
- PR Newswire
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 study evaluating CAPLYTA® (lumateperone) for the... ...
- Earnings Call Transcripts
JNJ - 1774424 - JOHNSON & JOHNSON
Good afternoon, everybody. My name is Andrew Calloway. I'm responsible for healthcare investment banking here at Deutsche Bank. I've joined by my partner, John Guskin, who's responsible for our medtech effort. And we are ...
- Earnings Call Transcripts
Deutsche Bank Healthcare Summit - JOHNSON & JOHNSON
Good afternoon, everybody. My name is Andrew Calloway. I'm responsible for healthcare investment banking here at Deutsche Bank. I've joined by my partner, John Guskin, who's responsible for our medtech effort. And we are ...
- PR Newswire
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab ... ...